Key Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$277 Hold
5
– – ﹤0.01% 777
2026
Q2
$273 Hold
5
– – ﹤0.01% 705
2026
Q1
$238 Hold
5
– – ﹤0.01% 665
2025
Q4
$262 Buy
+5
New +$299 ﹤0.01% 508

Other funds holding CRSP

Key Capital Management's CRSP Position: Q3 2026 in Review

Key Capital Management held its CRISPR Therapeutics (CRSP) position steady in Q3 2026 at 5 shares worth $277. The position accounts for ﹤0.01% of the portfolio, ranked #777.

Key Capital Management first reported a position in CRSP in Q4 2025 and has held it in 4 quarters since. 504 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Key Capital Management held 5 shares of CRISPR Therapeutics worth $277 as of Q3 2026.
  • Key Capital Management left its CRISPR Therapeutics share count unchanged in Q3 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Key Capital Management's portfolio in Q3 2026, its #777 holding.
  • Key Capital Management first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 504 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Key Capital Management's 13F filing for Q3 2026, filed 3 Nov 2026.